Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis
2017-004903-33Phase 2Unknown
- Sponsor
- Orphazyme A/S
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sporadic inclusion body myositis (sIBM) comparing Arimoclomol arm with Placebo arm (2 arms). Primary endpoint: IBM Functional Rating Scale total score change. Status: unknown.
02
Drugs
arimoclomol
03
Conditions
sporadic inclusion body myositis (sIBM)
Beyond the preview
Go deeper on 2017-004903-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004903-33.